JCLA:检测结核分枝杆菌RT-LAMP和LAMP法的评估

2018-05-31 MedSci MedSci原创

目前用于检测结核分枝杆菌(Mtb)的方法在临床上并不是最优化的。其中,标准培养方法(SCM)速度慢,成本昂贵且可能不可靠,而环介导的等温扩增(LAMP)不能区分活Mtb。 该研究比较了用于检测Mtb的几种方法,包括逆转录(RT)-LAMP,LAMP和SCM。对9种的结核分枝杆菌(H37Rv,胞内分枝杆菌,海分枝杆菌,堪萨斯分枝杆菌,鸟分枝杆菌,M.苦参,耻垢分枝杆菌,偶发分枝杆菌,和龟分枝杆菌)

目前用于检测结核分枝杆菌(Mtb)的方法在临床上并不是最优化的。其中,标准培养方法(SCM)速度慢,成本昂贵且可能不可靠,而环介导的等温扩增(LAMP)不能区分活Mtb

该研究比较了用于检测Mtb的几种方法,包括逆转录(RT-LAMPLAMPSCM。对9种的结核分枝杆菌(H37Rv,胞内分枝杆菌,海分枝杆菌,堪萨斯分枝杆菌,鸟分枝杆菌,M.苦参,耻垢分枝杆菌,偶发分枝杆菌,和龟分枝杆菌); 3种非分枝杆菌种(金黄色葡萄球菌,铜绿假单胞菌和肺炎克雷伯氏菌)在第一个实验中测试引物的灵敏度和特异性。第二个实验使用罗氏固体培养物(SCM),LAMPRT-LAMP100名患有结核病的患者(临床)和22名来自无结核病患者(对照)的痰标本中检测Mtb的存在。

结果显示SCMLAMPRT-LAMP测试方法的Mtb阳性率分别为88%,92%和100%。RT-LAMPSCM之间的检测率差异显著,但RT-LAMPLAMP相当。在对照组中,所有三种方法的检出率均为零。

研究结果表明,这些方法的特异性是相似的。RT-LAMP的灵敏度比LAMP高10倍。与LAMP不同,RT-LAMP可以识别活细菌,并且能够检测到Mtb的单个拷贝。在SCM,LAMP和RT-LAMP中,RT-LAMP最适合广泛用于中国的下级医院和诊所检测痰标本中的Mtb。

原始出处:

Shuo Wang  Min Zhao, Dandan Wu  Jiwen Kang, Evaluation of the RTLAMP and LAMP methods for detection of Mycobacterium tuberculosis

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2057628, encodeId=67c7205e62840, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sat Feb 09 09:07:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942692, encodeId=b3d21942692da, content=<a href='/topic/show?id=42a831e76af' target=_blank style='color:#2F92EE;'>#分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31776, encryptionId=42a831e76af, topicName=分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Nov 11 14:07:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254180, encodeId=cec31254180aa, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439745, encodeId=b5081439e4590, content=<a href='/topic/show?id=89d9e86326c' target=_blank style='color:#2F92EE;'>#结核分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78632, encryptionId=89d9e86326c, topicName=结核分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320330, encodeId=678f32033085, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 31 20:22:33 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2019-02-09 lxg951
  2. [GetPortalCommentsPageByObjectIdResponse(id=2057628, encodeId=67c7205e62840, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sat Feb 09 09:07:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942692, encodeId=b3d21942692da, content=<a href='/topic/show?id=42a831e76af' target=_blank style='color:#2F92EE;'>#分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31776, encryptionId=42a831e76af, topicName=分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Nov 11 14:07:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254180, encodeId=cec31254180aa, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439745, encodeId=b5081439e4590, content=<a href='/topic/show?id=89d9e86326c' target=_blank style='color:#2F92EE;'>#结核分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78632, encryptionId=89d9e86326c, topicName=结核分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320330, encodeId=678f32033085, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 31 20:22:33 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2057628, encodeId=67c7205e62840, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sat Feb 09 09:07:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942692, encodeId=b3d21942692da, content=<a href='/topic/show?id=42a831e76af' target=_blank style='color:#2F92EE;'>#分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31776, encryptionId=42a831e76af, topicName=分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Nov 11 14:07:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254180, encodeId=cec31254180aa, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439745, encodeId=b5081439e4590, content=<a href='/topic/show?id=89d9e86326c' target=_blank style='color:#2F92EE;'>#结核分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78632, encryptionId=89d9e86326c, topicName=结核分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320330, encodeId=678f32033085, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 31 20:22:33 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2057628, encodeId=67c7205e62840, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sat Feb 09 09:07:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942692, encodeId=b3d21942692da, content=<a href='/topic/show?id=42a831e76af' target=_blank style='color:#2F92EE;'>#分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31776, encryptionId=42a831e76af, topicName=分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Nov 11 14:07:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254180, encodeId=cec31254180aa, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439745, encodeId=b5081439e4590, content=<a href='/topic/show?id=89d9e86326c' target=_blank style='color:#2F92EE;'>#结核分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78632, encryptionId=89d9e86326c, topicName=结核分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320330, encodeId=678f32033085, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 31 20:22:33 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2057628, encodeId=67c7205e62840, content=<a href='/topic/show?id=c02b106e29a' target=_blank style='color:#2F92EE;'>#LAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10672, encryptionId=c02b106e29a, topicName=LAM)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sat Feb 09 09:07:00 CST 2019, time=2019-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1942692, encodeId=b3d21942692da, content=<a href='/topic/show?id=42a831e76af' target=_blank style='color:#2F92EE;'>#分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31776, encryptionId=42a831e76af, topicName=分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=920c231, createdName=lixiaol, createdTime=Sun Nov 11 14:07:00 CST 2018, time=2018-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254180, encodeId=cec31254180aa, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439745, encodeId=b5081439e4590, content=<a href='/topic/show?id=89d9e86326c' target=_blank style='color:#2F92EE;'>#结核分枝杆菌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78632, encryptionId=89d9e86326c, topicName=结核分枝杆菌)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Sat Jun 02 11:07:00 CST 2018, time=2018-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=320330, encodeId=678f32033085, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Thu May 31 20:22:33 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2018-05-31 天地飞扬

    了解一下.谢谢分享!

    0

相关资讯

Nat Commun:微生物所揭示结核分枝杆菌与宿主相互作用的分子机制

由结核分枝杆菌(Mycobacterium tuberculosis, Mtb)引起的结核病是一种古老的慢性传染病,并且至今仍是全球死亡人数最多的单一传染病。据世界卫生组织(WHO)报道:2015年全球有1040万新发结核病患者,有180万人死于结核病。

Science:利用小分子SMARt-420逆转结核分枝杆菌的抗生素耐药性

在一项新的研究中,来自瑞典、法国、比利时和瑞士的一个研究团队发现一种方法逆转对一种用于治疗肺结核的抗生素药物产生的耐药性。在他们发表在2017年3月17日的Science期刊上的论文中,该团队描述了他们如何筛选激活用于活化ethionaide的不同通路的化合物。Ethionaide是一种被用来治疗肺结核的前体分子,在体内经过代谢后产生一种真正有

FRONT CELL INFECT MI:比较基因组学分析结核分枝杆菌差异

据WHO结核年报报道,2015年全球新增结核病例1,040万,死亡180万。另外,目前全球约有约20亿人口为结核菌携带者,感染者中约1/10的人最终会发展为活动性结核。结核分枝杆菌复合体(MTBC)是引发结核病的元凶,其家族成员在基因组序列上极为保守,一致性超过99%,但是不同谱系的菌株在毒力、宿主适应性等方面存在较大表型差异,这可能是MTBC菌株与不同的宿主之间长期共进化的结果。

Cellul Microbio:结核分枝杆菌入侵机制研究取得进展

中国科学院微生物研究所刘翠华研究团队致力于研究Mtb等重要病原菌与宿主相互作用的分子机制,发现了Mtb通过调控宿主细胞功能促进对宿主固有免疫逃逸及肺癌发生发展的新机制,并揭示了病原菌与宿主间相互博弈的动态过程及分子机制,为抗结核药物研发提供了新思路和特异靶点。

Eur Respir J:解释结核分枝杆菌突变与耐药表型关系的标准化方法!

这项研究提供了一种标准化和全面的解释突变的方法,以作为结核杆菌耐药表型的预测因子。这些数据为分子诊断和新一代测序提供了临床解释,并可能实现耐药结核患者有效的个体化治疗。

HIV合并结核分枝杆菌感染诊治专家共识

为了进一步规范HIV/MTB合并感染的诊治,中华医学会感染病学分会艾滋病学组和中华医学会热带病与寄生虫学分会艾滋病学组共同制订了此专家共识。本共识是基于我国HIV/MTB合并感染的流行现状、临床实践和研究进展进行编写,同时参考了国内外HIV/MTB合并感染诊疗相关指南。本共识将随着HIV/MTB合并感染流行病学的变迁以及临床与基础研究的进步而定期更新。